ML
SLDB icon

McAdam LLC’s Solid Biosciences SLDB Stock Holding History

McAdam LLC’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-3
Closed – – 786
2018
Q1 		$0 Buy
+3
New +$1.01K ﹤0.01% 798

Other funds holding SLDB

JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

McAdam LLC's SLDB Position: Q2 2018 in Review

McAdam LLC sold out of Solid Biosciences (SLDB) in Q2 2018, closing a stake of 3 shares.

McAdam LLC first reported a position in SLDB in Q1 2018 and held it in 1 quarter. The position peaked at $0 in Q1 2018. 64 funds tracked by Wall St. Rank hold SLDB as of Q2 2018.

  • McAdam LLC reported no remaining Solid Biosciences position as of Q2 2018 after selling out during the quarter.
  • McAdam LLC sold 3 Solid Biosciences shares in Q2 2018.
  • McAdam LLC first reported a position in Solid Biosciences in Q1 2018 and held it in 1 quarter.
  • McAdam LLC's Solid Biosciences position peaked at $0 in Q1 2018.
  • 64 funds tracked by Wall St. Rank held Solid Biosciences as of Q2 2018.

Based on McAdam LLC's 13F filing for Q2 2018, filed 22 Aug 2018.